Kamal A - Search Results

1

Orally active purine-based inhibitors of the heat shock protein 90.

Biamonte MA, Shi J, Hong K, Hurst DC, Zhang L, Fan J, Busch DJ, Karjian PL, Maldonado AA, Sensintaffar JL, Yang YC, Kamal A, Lough RE, Lundgren K, Burrows FJ, Timony GA, Boehm MF, Kasibhatla SR. Biamonte MA, et al. Among authors: kamal a. J Med Chem. 2006 Jan 26;49(2):817-28. doi: 10.1021/jm0503087. J Med Chem. 2006. PMID: 16420067

2

Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.

Le Brazidec JY, Kamal A, Busch D, Thao L, Zhang L, Timony G, Grecko R, Trent K, Lough R, Salazar T, Khan S, Burrows F, Boehm MF. Le Brazidec JY, et al. Among authors: kamal a. J Med Chem. 2004 Jul 15;47(15):3865-73. doi: 10.1021/jm0306125. J Med Chem. 2004. PMID: 15239664

3

7'-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors.

Zhang L, Fan J, Vu K, Hong K, Le Brazidec JY, Shi J, Biamonte M, Busch DJ, Lough RE, Grecko R, Ran Y, Sensintaffar JL, Kamal A, Lundgren K, Burrows FJ, Mansfield R, Timony GA, Ulm EH, Kasibhatla SR, Boehm MF. Zhang L, et al. Among authors: kamal a. J Med Chem. 2006 Aug 24;49(17):5352-62. doi: 10.1021/jm051146h. J Med Chem. 2006. PMID: 16913725

4

Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.

Kasibhatla SR, Hong K, Biamonte MA, Busch DJ, Karjian PL, Sensintaffar JL, Kamal A, Lough RE, Brekken J, Lundgren K, Grecko R, Timony GA, Ran Y, Mansfield R, Fritz LC, Ulm E, Burrows FJ, Boehm MF. Kasibhatla SR, et al. Among authors: kamal a. J Med Chem. 2007 Jun 14;50(12):2767-78. doi: 10.1021/jm050752+. Epub 2007 May 8. J Med Chem. 2007. PMID: 17488003

5

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.

Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, Busch DJ, Neely L, Sensintaffar JL, Yang YC, McKenzie A, Friedman J, Scannevin R, Kamal A, Hong K, Kasibhatla SR, Boehm MF, Burrows FJ. Lundgren K, et al. Among authors: kamal a. Mol Cancer Ther. 2009 Apr;8(4):921-9. doi: 10.1158/1535-7163.MCT-08-0758. Mol Cancer Ther. 2009. PMID: 19372565

6

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.

Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ. Kamal A, et al. Nature. 2003 Sep 25;425(6956):407-10. doi: 10.1038/nature01913. Nature. 2003. PMID: 14508491 Free article.

7

Therapeutic and diagnostic implications of Hsp90 activation.

Kamal A, Boehm MF, Burrows FJ. Kamal A, et al. Trends Mol Med. 2004 Jun;10(6):283-90. doi: 10.1016/j.molmed.2004.04.006. Trends Mol Med. 2004. PMID: 15177193 Free PMC article. Review.

8

Hsp90 activation and cell cycle regulation.

Burrows F, Zhang H, Kamal A. Burrows F, et al. Among authors: kamal a. Cell Cycle. 2004 Dec;3(12):1530-6. doi: 10.4161/cc.3.12.1277. Epub 2004 Dec 30. Cell Cycle. 2004. PMID: 15539946 Review.

9

Hsp90 inhibitors as selective anticancer drugs.

Kamal A, Burrows FJ. Kamal A, et al. Discov Med. 2004 Oct;4(23):277-80. Discov Med. 2004. PMID: 20704959 Free article.

10

ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.

Castro JE, Prada CE, Loria O, Kamal A, Chen L, Burrows FJ, Kipps TJ. Castro JE, et al. Among authors: kamal a. Blood. 2005 Oct 1;106(7):2506-12. doi: 10.1182/blood-2005-03-1099. Epub 2005 Jun 21. Blood. 2005. PMID: 15972449 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,922 results

Search Page

Filters